NEW
Kesimpta

Kesimpta

Manufacturer:

Novartis

Distributor:

Zuellig
Concise Prescribing Info
Contents
Ofatumumab
Indications/Uses
Adults w/ relapsing forms of multiple sclerosis.
Dosage/Direction for Use
20 mg SC inj w/ initial dosing at wk 0, 1 & 2, followed by subsequent mthly dosing starting at wk 4.
Contraindications
Special Precautions
Inj-related reactions generally occur w/in 24 hr & predominantly following the 1st inj. Potential for an increased risk of infections. Delay administration in patients w/ an active infection until the infection is resolved. If progressive multifocal leukoencephalopathy (PML) is suspected, suspend treatment until PML has been excluded. Patients w/ active hepatitis B disease should not be treated w/ Kesimpta. Perform HBV screening in all patients before treatment initiation. Administer all immunisations at least 4 wk for live or live-attenuated vaccines & 2 wk for inactivated vaccines prior to treatment initiation. May interfere w/ the effectiveness of inactivated vaccines. Vaccination w/ live or live-attenuated vaccines is not recommended during treatment, & until B-cell repletion after discontinuation. Do not administer before the recovery of B-cell counts has been confirmed in infants of mothers treated w/ Kesimpta during pregnancy. Women of childbearing potential should use effective contraception during treatment & for 6 mth after the last administration. Pregnancy & lactation. Childn 0-18 yr.
Adverse Reactions
URTI; inj site reactions (local); inj-related reactions (systemic).
Drug Interactions
Complete immunisations prior to start of therapy as response to vaccination could be impaired when B cells are depleted. Potential additive immunosuppressive effects w/ medicinal products w/ prolonged immune effects eg, ocrelizumab, cladribine, fingolimod, natalizumab, teriflunomide, mitoxantrone, dimethyl fumarate.
MIMS Class
Immunosuppressants
ATC Classification
L04AA52 - ofatumumab ; Belongs to the class of selective immunosuppressive agents. Used to induce immunosuppression.
Presentation/Packing
Form
Kesimpta soln for inj 20 mg/0.4 mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in